search
Back to results

Telemedicine for Children With Sickle Cell Disease

Primary Purpose

Anemia, Sickle Cell

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Types of Telemedicine Delivery Models
Sponsored by
Indiana University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Anemia, Sickle Cell

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must be between 0 to 21 years old with Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic.
  • The family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence.
  • TeleSCD model participants must live within 1 hour of the pre-identified telemedicine sites, while VirtualSCD model participants must live within the city limits of the pre-identified area.

Exclusion Criteria:

  • If a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this.

Sites / Locations

  • Indiana UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Hub and Spoke

Direct to Consumer

Arm Description

Outcomes

Primary Outcome Measures

Measuring adherence to appointment in sickle cell care.
Failed appointments in Electronic Medical Record - no more than one failed appointment during pilot year.
Measuring adherence to lab draws in sickle cell care.
Adherence to lab draws - a minimum of one complete blood count per six months.
Measuring healthcare utilization pre and post telemedicine participation.
Will determine the frequency of 1) vasoocclusive pain episode; 2) acute chest syndrome; 3) Emergency department visits; 4) hospitalizations. This data will be collected through chart abstraction from Electronic Medical Record one year prior to study entry and one year on study.
Measuring collaboration of primary care provider and subspecialty care provider.
Documentation of Primary Care Provider communication of visits in the electronic medical record at least 70% of the time.
Provider Feedback
Telemedicine Acceptance Questionnaire (TAQ) - will be given to all providers participating in telemedicine visits after every telemedicine visit. 0-5 Likert scale
Caregiver feedback
Telemedicine satisfaction survey (TESS) - administered to caregivers following each telemedicine visit. 0-5 Likert scale

Secondary Outcome Measures

Full Information

First Posted
June 15, 2021
Last Updated
September 25, 2023
Sponsor
Indiana University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05087303
Brief Title
Telemedicine for Children With Sickle Cell Disease
Official Title
Telemedicine for Pediatric Sickle Cell Patients in Medically Underserved Areas
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 23, 2022 (Actual)
Primary Completion Date
October 1, 2025 (Anticipated)
Study Completion Date
October 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved. Aim 1: Adapt two telemedicine models (i.e., hub-and-spoke; direct-to-consumer) for use with children with SCD using caregiver input from our preliminary K12 work. Aim 2: Demonstrate the feasibility of the telemedicine models developed in Aim 1 as the models undergo successive stakeholder refinement during use in actual clinical care. Aim 3: Evaluate the effectiveness of the refined models from Aim 2 in a pre/post study by assessing (a) process of care measures, (b) provider satisfaction, (c) caregiver/patient-centered outcomes, and (d) clinical outcomes and healthcare utilization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia, Sickle Cell

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hub and Spoke
Arm Type
Active Comparator
Arm Title
Direct to Consumer
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
Types of Telemedicine Delivery Models
Intervention Description
Each arm delivers standard sickle cell care using a different model based on patient location.
Primary Outcome Measure Information:
Title
Measuring adherence to appointment in sickle cell care.
Description
Failed appointments in Electronic Medical Record - no more than one failed appointment during pilot year.
Time Frame
1 year
Title
Measuring adherence to lab draws in sickle cell care.
Description
Adherence to lab draws - a minimum of one complete blood count per six months.
Time Frame
6 months
Title
Measuring healthcare utilization pre and post telemedicine participation.
Description
Will determine the frequency of 1) vasoocclusive pain episode; 2) acute chest syndrome; 3) Emergency department visits; 4) hospitalizations. This data will be collected through chart abstraction from Electronic Medical Record one year prior to study entry and one year on study.
Time Frame
1 year
Title
Measuring collaboration of primary care provider and subspecialty care provider.
Description
Documentation of Primary Care Provider communication of visits in the electronic medical record at least 70% of the time.
Time Frame
1 year
Title
Provider Feedback
Description
Telemedicine Acceptance Questionnaire (TAQ) - will be given to all providers participating in telemedicine visits after every telemedicine visit. 0-5 Likert scale
Time Frame
1 year
Title
Caregiver feedback
Description
Telemedicine satisfaction survey (TESS) - administered to caregivers following each telemedicine visit. 0-5 Likert scale
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Caregivers must be 18 years or older, who have children between 0 to 21 years old with a diagnosis of Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic. Adolescent patients 16 years and older are also able to participate in interviews/surveys. The family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence. TeleSCD model participants must live within 1 hour of the pre-identified telemedicine sites, while VirtualSCD model participants must live within the city limits of the pre-identified area. Exclusion Criteria: If a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Seethal Jacob, MD
Phone
317-278-9662
Email
seejacob@iu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seethal Jacob, MD
Organizational Affiliation
Indiana University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Seethal Jacob, MD
Phone
317-278-9662
Email
seejacob@iu.edu

12. IPD Sharing Statement

Learn more about this trial

Telemedicine for Children With Sickle Cell Disease

We'll reach out to this number within 24 hrs